Education
About Us
Working with TipRanks
Follow Us
Pelthos Therapeutics (PTHS)
:PTHS
PTHS Stock Chart & Stats
$26.98
--
Market closed
$26.98
--
Day’s Range― - ―
52-Week Range$5.89 - $54.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.94K
Market Cap
$81.80M
Enterprise Value$74.95M
Total Cash (Recent Filing)$14.25M
Total Debt (Recent Filing)$3.48M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Nov 13, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,086,681
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)-2.55
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue10.12
Enterprise Value/Gross Profit18.63
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$59.80Price Target Upside121.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-15.18
Revenue Forecast (FY)$21.40M
Bulls Say, Bears Say
Bulls Say
Market PotentialZelsuvmi addresses a clearly defined unmet need and is positioned to participate in a large, established market.
Product LaunchPTHS is a commercial stage biopharma company which launched its first drug, Zelsuvmi, the first and only at-home treatment indicated for the treatment of molluscum contagiosum, a large, underserved market.
Sales And DistributionZelsuvmi has been added to the Medicaid formularies in New York, Texas, and Alabama without needing prior authorization, increasing its accessibility and potential sales volume.
Bears Say
CompetitionVerrica Pharmaceuticals is seen as a primary competitive threat to Zelsuvmi with its FDA-approved MC drug Ycanth, which offers a different application process and cost structure.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $5.89 and its highest was $54.29 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $81.80M.
When is Pelthos Therapeutics’s upcoming earnings report date?
Pelthos Therapeutics’s upcoming earnings report date is Nov 13, 2025 which is 43 days ago.
How were Pelthos Therapeutics’s earnings last quarter?
Pelthos Therapeutics released its earnings results on Aug 18, 2025. The company reported -$5.38 earnings per share for the quarter, beating the consensus estimate of -$5.82 by $0.44.
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate is -0.58.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,086,681 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Pelthos Therapeutics reported an EPS of -$5.38 in its last earnings report, beating expectations of -$5.82. Following the earnings report the stock price went down -7.273%.
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.80 (121.65% Upside)
$59.80 (121.65% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $280.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
315.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5808.39%
Trailing 12-Months
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
PTHS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Pelthos' strong launch of ZELSUVMI and strategic growth plans, including a sales force expansion and acquisition of Xepi. However, the company faces challenges with high operating losses and uncertain long-term GTN levels. Overall, the positive aspects of strong revenue growth and strategic positioning outweigh the financial challenges.View all PTHS earnings summariesPTHS Stock 12 Month Forecast
Average Price Target
$59.80
▲(121.65% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―